--- ---

Clinical Scorecard: Characterization of Infusion-Related Reactions and Premedication Practices in Multiple Sclerosis Patients Treated with Ublituximab: A Multicenter Real-World Analysis

At a Glance

Key Highlights

• 34.8% of patients experienced mild to moderate IRRs.

• All patients received premedication prior to ublituximab infusion.

• Acetaminophen dosage was significantly associated with IRR occurrence.

• IRRs were more common at the first infusion, with a decline in subsequent infusions.

• No independent predictors of IRRs were identified.

Guideline-Based Recommendations

Diagnosis

• Patients diagnosed with any subtype of multiple sclerosis.

Management

• Ublituximab infusions should be administered with premedication to mitigate IRRs.

Monitoring & Follow-up

• Monitor for IRRs during and after ublituximab infusion.

Risks

• Risk of infusion-related reactions, particularly during the first infusion.

Patient & Prescribing Data

Patients with multiple sclerosis receiving ublituximab.

Premedication practices vary across centers; acetaminophen is a key component associated with IRR occurrence.

Clinical Best Practices

• Administer premedication including antihistamines and corticosteroids before ublituximab infusion.

• Monitor patients closely for IRRs, especially during the first infusion.

Related Resources & Content

• “Efficacy and safety of ublituximab for relapsing multiple sclerosis.” Journal of Neurology, 2025, Volume 272, Issue 10

• Multiple Sclerosis Discovery Forum - A resource for the latest research and developments in multiple sclerosis treatments.

• National Multiple Sclerosis Society - Offers comprehensive information on MS, treatment options, and patient support.

• ClinicalTrials.gov - A database of privately and publicly funded clinical studies conducted around the world, including studies on ublituximab.

--- ---